{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002720","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.830582+00:00","generated_at":"2026-05-15T03:53:47.965385+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission","bullets":["Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).","Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.","OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).","Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).","Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002720","json":"https://secwatch.observer/filing/0001171843-26-002720.json","markdown":"https://secwatch.observer/filing/0001171843-26-002720.md","text":"https://secwatch.observer/filing/0001171843-26-002720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/0001171843-26-002720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/f8k_042526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:53:47.965385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}